China SXT Pharmaceuticals (SXTC) Receivables (2018 - 2025)

China SXT Pharmaceuticals' Receivables history runs 8 years deep, the most recent figure standing at $2.7 million for Q3 2025.

• In Q3 2025, Receivables rose 74.93% year-over-year to $2.7 million; the TTM figure through Sep 2025 stood at $2.7 million (up 74.93% YoY), while the FY2025 annual figure was $3.8 million, up 21.45% from the prior year.
• Receivables was $2.7 million for Q3 2025 at China SXT Pharmaceuticals, up from $1.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $6.9 million in Q3 2021 to a low of $1.3 million in Q3 2023.
• Historically, Receivables has averaged $3.5 million across 5 years, with a median of $3.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Receivables tumbled 78.41% in 2023, then surged 74.93% in 2025.
• A 5-year view of Receivables shows it stood at $6.9 million in 2021, then fell by 11.51% to $6.1 million in 2022, then plunged by 78.41% to $1.3 million in 2023, then increased by 17.76% to $1.5 million in 2024, then soared by 74.93% to $2.7 million in 2025.
• The last three Receivables figures came in at $2.7 million (Q3 2025), $1.7 million (Q1 2025), and $1.5 million (Q3 2024), per Business Quant data.